VBI Vaccines Inc.
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vacci… Read more
VBI Vaccines Inc. (VBIVQ) - Net Assets
Latest net assets as of March 2024: $-5.47 Million USD
Based on the latest financial reports, VBI Vaccines Inc. (VBIVQ) has net assets worth $-5.47 Million USD as of March 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($75.44 Million) and total liabilities ($80.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-5.47 Million |
| % of Total Assets | -7.25% |
| Annual Growth Rate | -64.77% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 29.46 |
VBI Vaccines Inc. - Net Assets Trend (2020–2023)
This chart illustrates how VBI Vaccines Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for VBI Vaccines Inc. (2020–2023)
The table below shows the annual net assets of VBI Vaccines Inc. from 2020 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $7.53 Million | -88.27% |
| 2022-12-31 | $64.16 Million | -55.41% |
| 2021-12-31 | $143.88 Million | -16.20% |
| 2020-12-31 | $171.71 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to VBI Vaccines Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27382700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $589.97 Million | 7838.08% |
| Total Equity | $7.53 Million | 100.00% |
VBI Vaccines Inc. Competitors by Market Cap
The table below lists competitors of VBI Vaccines Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TERTIARY MINERALS - Frankfurt Stock Exchang
F:TMU
|
$4.75 |
|
KEDCO
STU:KEU
|
$4.76 |
|
Grillit Inc.
PINK:GRLT
|
$4.77 |
|
ALBA MINERAL RES LS-0001
F:9AB
|
$4.79 |
|
Eastern Asteria Inc
PINK:EATR
|
$4.75 |
|
Aryx Therapeutics I
PINK:ARYX
|
$4.75 |
|
WIJAYA KARYA (5AA.SG)
STU:5AA
|
$4.75 |
|
Air Berlin PLC
HM:AB1
|
$4.75 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VBI Vaccines Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 64,163,000 to 7,527,000, a change of -56,636,000 (-88.3%).
- Net loss of 92,836,000 reduced equity.
- New share issuances of 24,273,000 increased equity.
- Other factors increased equity by 11,927,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-92.84 Million | -1233.37% |
| Share Issuances | $24.27 Million | +322.48% |
| Other Changes | $11.93 Million | +158.46% |
| Total Change | $- | -88.27% |
Book Value vs Market Value Analysis
This analysis compares VBI Vaccines Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $20.85 | $0.00 | x |
| 2021-12-31 | $16.71 | $0.00 | x |
| 2022-12-31 | $7.45 | $0.00 | x |
| 2023-12-31 | $0.31 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently VBI Vaccines Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1233.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1069.29%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 11.55x
- Recent ROE (-1233.37%) is below the historical average (-371.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -26.92% | -4357.21% | 0.01x | 1.22x | $-63.40 Million |
| 2021 | -48.48% | -11054.36% | 0.00x | 1.46x | $-84.14 Million |
| 2022 | -176.59% | -10471.63% | 0.01x | 2.42x | $-119.72 Million |
| 2023 | -1233.37% | -1069.29% | 0.10x | 11.55x | $-93.59 Million |
Industry Comparison
This section compares VBI Vaccines Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VBI Vaccines Inc. (VBIVQ) | $-5.47 Million | -26.92% | N/A | $4.75 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |